On 19 June 2018 the Senate referred to the Foreign Affairs, Defence and Trade References Committee a range of matters relating to the ADF use of Mefloquine and Tafenoquine for inquiry and report by 17 September 2018. 
The full terms of reference are to inquire with particular reference to:
(a) the current and past policies and practices for:
(i) prescribing Quinoline anti-malarial drugs to ADF personnel, and
(ii) identifying and reporting adverse drug reactions from Quinoline anti-malarial drugs among ADF personnel;
(b) the nature and extent of any adverse health effects of those who have taken Mefloquine/Tafenoquine on serving and former ADF personnel;
(c) the support available for partners, carers and families of personnel who experience any adverse health effects of Quinoline anti-malarial drugs;
(d) a comparison of international evidence/literature available on the impact of Quinoline anti-malarials;
(e) how other governments have responded to claims regarding Quinoline anti-malarials; and
(f) any other related matters.
The purpose of this letter of invitation is to draw your attention to the inquiry and to invite you or your organisation to make a written submission to the committee by 31 July 2018.
